First patients test promising new cancer drug combo

NCT ID NCT06422520

Summary

This is the first study in people to test a new cancer drug called BGB-C354. Researchers want to see if it is safe, how the body processes it, and if it shows early signs of fighting cancer, both by itself and when combined with another immunotherapy drug. The study will enroll about 120 adults with advanced solid tumors that have not responded to standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215-5418, United States

  • Florida Cancer Specialist Research Institute Lake Nona

    Orlando, Florida, 32827-7400, United States

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Jilin Cancer Hospital

    Changchun, Jilin, 130021, China

  • Liaoning Cancer Hospital and Institute

    Shenyang, Liaoning, 110042, China

  • Next Oncology

    Austin, Texas, 78758, United States

  • One Clinical Research

    Nedlands, Western Australia, WA 6009, Australia

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, VIC 3065, Australia

  • The Alfred Hospital

    Melbourne, Victoria, VIC 3004, Australia

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110-1010, United States

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

  • Westmead Hospital

    Westmead, New South Wales, NSW 2145, Australia

Conditions

Explore the condition pages connected to this study.